Micro-Cap Biotech Skyrockets on FDA Pediatric Disease Nod

Sponsored:

Thursday, May 22, 2025

FDA approvals are often market-moving events, and today a micro-cap biotech company saw its shares surge after receiving Rare Pediatric Disease designation from the FDA.

Relief Therapeutics Holding SA (OTCQB:RLFTF) (OTCQB:RLFTY) announced this morning that the U.S. FDA has granted Rare Pediatric Disease (RPD) designation to its drug candidate RLF-TD011 for the treatment of epidermolysis bullosa (EB), a rare genetic skin disorder. This follows a previous Orphan Drug Designation for the same condition. RLF-TD011 is a hypotonic acid-oxidizing solution containing hypochlorous acid, developed to offer antimicrobial and anti-inflammatory effects while promoting a healing wound environment. The company has reported encouraging clinical results, highlighting the drug's potential to improve EB wound care by modulating the wound microbiome and reducing harmful bacterial colonization.

"The FDA's decision to grant Rare Pediatric Disease designation to RLF-TD011 underscores both the critical need for new options for patients living with EB and the potential of our investigational therapy," said Giorgio Reiner, chief scientific officer of Relief. "We look forward to continued engagement with the FDA and to sharing the next steps in our development plan following our upcoming pre-IND meeting."

The FDA grants RPD designation to product candidates targeting serious or life-threatening diseases that primarily affect individuals aged 18 years or younger and impact fewer than 200,000 people in the U.S. Companies that receive marketing approval for an RPD-designated indication may be eligible-subject to certain conditions, including congressional reauthorization of the program for designations granted after December 20, 2024-to receive a Priority Review Voucher (PRV), which grants expedited FDA review for a future marketing application. These vouchers are transferable; in May 2025, a PRV awarded following the approval of a treatment for a rare form of EB was sold for $155 million.

Shares of RLFTF are surging on the news, currently up 49.62% at $3.89 while shares of RLFTY trade up 40.34% at $4.07 in late-morning trading.

Sponsored: